Home / Resource Library / Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE

Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE

Results of a study investigating ibrutinib combined with rituxiamb and bendamustine for treatment of MCL.